Systemic Therapy in Hepatocellular Carcinoma

Clinics in Liver Disease

Volumn 15, Issue 2, 2011, Pages 423-441

  Wrzesinski, Stephen H ^a,b   Taddei, Tamar H ^b,c   Strazzabosco, Mario ^c,d  

^a YALE CANCER CENTER   (United States)

^b VA CONNECTICUT HEALTHCARE SYSTEM   (United States)

^c YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF MILANO BICOCCA   (Italy)

Author keywords

Chemotherapy; Hepatocellular carcinoma; Systemic therapy

Indexed keywords

ALPHA FETOPROTEIN; ALPHA INTERFERON; ANGIOGENESIS INHIBITOR; BETA INTERFERON; BEVACIZUMAB; BRIVANIB; CAPECITABINE; CEDIRANIB; CETUXIMAB; CISPLATIN; DENDRITIC CELL VACCINE; DOXORUBICIN; ERLOTINIB; ETOPOSIDE; FLUOROURACIL; GEFITINIB; GEMCITABINE; IRINOTECAN; LINIFANIB; MITOXANTRONE; NOLATREXED; OXALIPLATIN; PACLITAXEL; PAZOPANIB; SELUMETINIB; SORAFENIB; SUNITINIB; TAMOXIFEN; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALATANIB; VATALANIB;

ABLATION THERAPY; ADVANCED CANCER; ANOREXIA; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER IMMUNOTHERAPY; CANCER PALLIATIVE THERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CARDIOTOXICITY; CELL EXPANSION; CELL ISOLATION; CELL PROLIFERATION; CHEMOEMBOLIZATION; CHILD TURCOTTE PUGH A CIRRHOSIS; COUGHING; CYTOPENIA; DIARRHEA; DRUG EFFICACY; DRUG ERUPTION; DRUG INDUCED HEADACHE; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; EFFECTOR CELL; FATIGUE; GASTROINTESTINAL HEMORRHAGE; HAND FOOT SYNDROME; HEPATITIS C VIRUS; HUMAN; HYPERTENSION; HYPONATREMIA; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; LOADING DRUG DOSE; LOW DRUG DOSE; MAXIMUM TOLERATED DOSE; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NAUSEA; NONHUMAN; OVERALL SURVIVAL; PERIPHERAL EDEMA; PROGRESSION FREE SURVIVAL; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SIDE EFFECT; SURVIVAL TIME; SYSTEMIC THERAPY; TREATMENT REFUSAL; UNSPECIFIED SIDE EFFECT; VIRUS REPLICATION; VOMITING; WEIGHT REDUCTION;

ANIMALS; ANTINEOPLASTIC AGENTS; CARCINOMA, HEPATOCELLULAR; CLINICAL TRIALS AS TOPIC; HUMANS; LIVER NEOPLASMS; LIVER NEOPLASMS, EXPERIMENTAL;

EID: 79959295770     PISSN: 10893261     EISSN: 15578224     Source Type: Journal    
DOI: 10.1016/j.cld.2011.03.002     Document Type: Review

References (83)

1. Bosch F.X., Ribes J., Diaz M., et al. Primary liver cancer: worldwide incidence and trends. Gastroenterology 2004, 127(5 Suppl 1):S5-S16.
2. Llovet J.M., Schwartz M., Mazzaferro V. Resection and liver transplantation for hepatocellular carcinoma. Semin Liver Dis 2005, 25(2):181-200.
3. Livraghi T., Meloni F., Di Stasi M., et al. Sustained complete response and complication rates after radiofrequency ablation of very early hepatocellular carcinoma in cirrhosis: is resection still the treatment of choice?. Hepatology 2008, 47(1):82-89.
4. Bruix J., Llovet J.M. Major achievements in hepatocellular carcinoma. Lancet 2009, 373(9664):614-616.
5. Bruix J., Sala M., Llovet J.M. Chemoembolization for hepatocellular carcinoma. Gastroenterology 2004, 127(5 Suppl 1):S179-S188.
6. Llovet J.M., Ricci S., Mazzaferro V., et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008, 359(4):378-390.
7. Thomas M.B., Jaffe D., Choti M.M., et al. Hepatocellular carcinoma: consensus recommendations of the National Cancer Institute Clinical Trials Planning Meeting. J Clin Oncol 2010, 28(25):3994-4005.
8. Olweny C.L., Toya T., Katongole-Mbidde E., et al. Treatment of hepatocellular carcinoma with adriamycin. Preliminary communication. Cancer 1975, 36(4):1250-1257.
9. Lai C.L., Wu P.C., Chan G.C., et al. Doxorubicin versus no antitumor therapy in inoperable hepatocellular carcinoma. A prospective randomized trial. Cancer 1988, 62(3):479-483.
10. Leung T.W., Patt Y.Z., Lau W.Y., et al. Complete pathological remission is possible with systemic combination chemotherapy for inoperable hepatocellular carcinoma. Clin Cancer Res 1999, 5(7):1676-1681.
11. Yeo W., Mok T.S., Zee B., et al. A randomized phase III study of doxorubicin versus cisplatin/interferon alpha-2b/doxorubicin/fluorouracil (PIAF) combination chemotherapy for unresectable hepatocellular carcinoma. J Natl Cancer Inst 2005, 97(20):1532-1538.
12. Kato A., Miyazaki M., Ambiru S., et al. Multidrug resistance gene (MDR-1) expression as a useful prognostic factor in patients with human hepatocellular carcinoma after surgical resection. J Surg Oncol 2001, 78(2):110-115.
13. Cheng A.L., Kang Y.K., Chen Z., et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 2009, 10(1):25-34.
14. Bolondi L., Caspary W., Bennouna J., et al. Clinical benefit of sorafenib in hepatitis C patients with hepatocellular carcinoma (HCC): subgroup analysis of the sharp trial. J Clin Oncol 2008, 26(Suppl):A129.
15. Himmelsbach K., Sauter D., Baumert T.F., et al. New aspects of an anti-tumour drug: sorafenib efficiently inhibits HCV replication. Gut 2009, 58(12):1644-1653.
16. Schoenleber S.J., Kurtz D.M., Talwalkar J.A., et al. Prognostic role of vascular endothelial growth factor in hepatocellular carcinoma: systematic review and meta-analysis. Br J Cancer 2009, 100(9):1385-1392.
17. Available at: Accessed April 1, 2011. http://www.clinicaltrials.gov/ct2/show/NCT00692770.
18. Available at: Accessed April 1, 2011. http://www.clinicaltrials.gov/ct2/show/NCT00855218.
19. Available at: Accessed April 1, 2011. http://www.clinicaltrials.gov/ct2/show/NCT0100497?term=NCT01004978.
20. Abou-Alfa G.K., Johnson P., Knox J.J., et al. Doxorubicin plus sorafenib vs doxorubicin alone in patients with advanced hepatocellular carcinoma: a randomized trial. JAMA 2010, 304(19):2154-2160.
21. Castells A., Bruix J., Bru C., et al. Treatment of hepatocellular carcinoma with tamoxifen: a double-blind placebo-controlled trial in 120 patients. Gastroenterology 1995, 109(3):917-922.
22. Liu C.L., Fan S.T., Ng I.O., et al. Treatment of advanced hepatocellular carcinoma with tamoxifen and the correlation with expression of hormone receptors: a prospective randomized study. Am J Gastroenterol 2000, 95(1):218-222.
23. Chow P.K., Tai B.C., Tan C.K., et al. High-dose tamoxifen in the treatment of inoperable hepatocellular carcinoma: a multicenter randomized controlled trial. Hepatology 2002, 36(5):1221-1226.
24. Nowak A.K., Stockler M.R., Chow P.K., et al. Use of tamoxifen in advanced-stage hepatocellular carcinoma. A systematic review. Cancer 2005, 103(7):1408-1414.
25. Manesis E.K., Giannoulis G., Zoumboulis P., et al. Treatment of hepatocellular carcinoma with combined suppression and inhibition of sex hormones: a randomized, controlled trial. Hepatology 1995, 21(6):1535-1542.
26. Becker G., Allgaier H.P., Olschewski M., et al. Long-acting octreotide versus placebo for treatment of advanced HCC: a randomized controlled double-blind study. Hepatology 2007, 45(1):9-15.
27. Miura H., Miyazaki T., Kuroda M., et al. Increased expression of vascular endothelial growth factor in human hepatocellular carcinoma. J Hepatol 1997, 27(5):854-861.
28. Poon R.T., Ho J.W., Tong C.S., et al. Prognostic significance of serum vascular endothelial growth factor and endostatin in patients with hepatocellular carcinoma. Br J Surg 2004, 91(10):1354-1360.
29. Jenab-Wolcott J., Giantonio B.J. Bevacizumab: current indications and future development for management of solid tumors. Expert Opin Biol Ther 2009, 9(4):507-517.
30. Jain R.K. Antiangiogenic therapy for cancer: current and emerging concepts. Oncology (Williston Park) 2005, 19(4 Suppl 3):7-16.
31. Siegel A.B., Cohen E.I., Ocean A., et al. Phase II trial evaluating the clinical and biologic effects of bevacizumab in unresectable hepatocellular carcinoma. J Clin Oncol 2008, 26(18):2992-2998.
32. Malka D., Dromain C., Farace F. Bevacizumab in patients with advanced hepatocellular carcinoma (HCC): preliminary results of a phase II study with circulating endothelial cell (CEC) monitoring. J Clin Oncol 2007, 25(Suppl 18):4570.
33. Zhu A.X., Blaszkowsky L.S., Ryan D.P., et al. Phase II study of gemcitabine and oxaliplatin in combination with bevacizumab in patients with advanced hepatocellular carcinoma. J Clin Oncol 2006, 24(12):1898-1903.
34. Thomas M.B., Morris J.S., Chadha R., et al. Phase II trial of the combination of bevacizumab and erlotinib in patients who have advanced hepatocellular carcinoma. J Clin Oncol 2009, 27(6):843-850.
35. Faris J.E., Michaelson M.D. Targeted therapies: sunitinib versus interferon-alpha in metastatic RCC. Nat Rev Clin Oncol 2010, 7(1):7-8.
36. Zhu A.X., Sahani D.V., Duda D.G., et al. Efficacy, safety, and potential biomarkers of sunitinib monotherapy in advanced hepatocellular carcinoma: a phase II study. J Clin Oncol 2009, 27(18):3027-3035.
37. Faivre S., Delbaldo C., Vera K., et al. Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer. J Clin Oncol 2006, 24(1):25-35.
38. Available at: Accessed April 1, 2011. http://clinicaltrials.gov/ct2/show/NCT00699374.
39. Huynh H., Ngo V.C., Fargnoli J., et al. Brivanib alaninate, a dual inhibitor of vascular endothelial growth factor receptor and fibroblast growth factor receptor tyrosine kinases, induces growth inhibition in mouse models of human hepatocellular carcinoma. Clin Cancer Res 2008, 14(19):6146-6153.
40. Raoul J., Finn R., Kang Y., et al. An open-label phase II study of first- and second-line treatment with brivanib in patients with hepatocellular carcinoma (HCC). J Clin Oncol 2009, 27(15S):4577.
41. Available at: Accessed April 1, 2011. http://clinicaltrials.gov/ct2/show/NCT00858871.
42. Available at: Accessed April 1, 2011. http://clinicaltrials.gov/ct2/show/NCT00825955.
43. Zhu A.X. Systemic treatment of hepatocellular carcinoma: dawn of a new era?. Ann Surg Oncol 2010, 17(5):1247-1256.
44. Alberts S, Morlan B, Kim G. NCCTG phase II trial (N044J) of AZD2171 for patients with hepatocellular carcinoma (HCC): interim review of toxicity. American Society of Clinical Oncology 2007 Gastrointestinal Cancers Symposium. Orlando (FL), June 1-5, 2007 [abstract A-186].
45. Toh H., Chen P., Carr B., et al. A phase II study of ABT-869 in hepatocellular carcinoma (HCC): interim analysis. J Clin Oncol 2009, 27(15S):4581.
46. Yau C., Chen P., Curtis C., et al. A phase I study of pazopanib in patients with advanced hepatocellular carcinoma. J Clin Oncol 2009, 27(15S):3561.
47. Koch I., Baron A., Roberts S. Influence of hepatic dysfunction on safety, tolerability, and pharmacokinetics (PK) of PTK787/ZK 222584 in patients (pts) with unresectable hepatocellular carcinoma (HCC). J Clin Oncol 2007, 23(Suppl):4134.
48. Whittaker S., Marais R., Zhu A.X. The role of signaling pathways in the development and treatment of hepatocellular carcinoma. Oncogene 2010, 29(36):4989-5005.
49. Philip P.A., Mahoney M.R., Allmer C., et al. Phase II study of Erlotinib (OSI-774) in patients with advanced hepatocellular cancer. J Clin Oncol 2005, 23(27):6657-6663.
50. Thomas M.B., Chadha R., Glover K., et al. Phase 2 study of erlotinib in patients with unresectable hepatocellular carcinoma. Cancer 2007, 110(5):1059-1067.
51. O'Dwyer P., Giantonio B., Levy D. Gefitinib in advanced unresectable hepatocellular carcinoma: results from the Eastern Cooperative Oncology Group's study E1203. J Clin Oncol 2006, 24(18S):A-4143. [abstract].
52. Markman B., Capdevila J., Elez E., et al. New trends in epidermal growth factor receptor-directed monoclonal antibodies. Immunotherapy 2009, 1(6):965-982.
53. Zhu A.X., Stuart K., Blaszkowsky L.S., et al. Phase 2 study of cetuximab in patients with advanced hepatocellular carcinoma. Cancer 2007, 110(3):581-589.
54. Grünwald V., Wilkens L., Gebel M., et al. A phase II open-label study of cetuximab in unresectable hepatocellular carcinoma: final results. J Clin Oncol 2007, 25(Suppl):4598.
55. Asnacios A., Fartoux L., Romano O., et al. Gemcitabine plus oxaliplatin (GEMOX) combined with cetuximab in patients with progressive advanced stage hepatocellular carcinoma: results of a multicenter phase 2 study. Cancer 2008, 112(12):2733-2739.
56. O'Neil B., Bernard S., Goldberg R. Phase II study of oxaliplatin, capecitabine, and cetuximab in advanced hepatocellular carcinoma. J Clin Oncol 2008, 26(Suppl):4604.
57. O'Neil B., Williams-Goff L., Kauh J., et al. A phase II study of AZD6244 in advanced or metastatic hepatocellular carcinoma. J Clin Oncol 2009, 27(15S):e15574.
58. Geissler E.K. The impact of mTOR inhibitors on the development of malignancy. Transplant Proc 2008, 40(Suppl 10):S32-S35.
59. Decaens T, Luciani A, Itti E. Pilot study of sirolimus in cirrhotic patients with advanced hepatocellular carcinoma. Gastrointestinal Cancers Symposium. San Francisco (CA), January 15-17, 2009 [abstract 244].
60. Overwijk W.W., Theoret M.R., Finkelstein S.E., et al. Tumor regression and autoimmunity after reversal of a functionally tolerant state of self-reactive CD8+ T cells. J Exp Med 2003, 198(4):569-580.
61. Lai C.L., Lau J.Y., Wu P.C., et al. Recombinant interferon-alpha in inoperable hepatocellular carcinoma: a randomized controlled trial. Hepatology 1993, 17(3):389-394.
62. Llovet J.M., Sala M., Castells L., et al. Randomized controlled trial of interferon treatment for advanced hepatocellular carcinoma. Hepatology 2000, 31(1):54-58.
63. Mazzaferro V., Romito R., Schiavo M., et al. Prevention of hepatocellular carcinoma recurrence with alpha-interferon after liver resection in HCV cirrhosis. Hepatology 2006, 44(6):1543-1554.
64. Lygidakis N.J., Kosmidis P., Ziras N., et al. Combined transarterial targeting locoregional immunotherapy-chemotherapy for patients with unresectable hepatocellular carcinoma: a new alternative for an old problem. J Interferon Cytokine Res 1995, 15(5):467-472.
65. Reinisch W., Holub M., Katz A., et al. Prospective pilot study of recombinant granulocyte-macrophage colony-stimulating factor and interferon-gamma in patients with inoperable hepatocellular carcinoma. J Immunother 2002, 25(6):489-499.
66. Giglia J.L., Antonia S.J., Berk L.B., et al. Systemic therapy for advanced hepatocellular carcinoma: past, present, and future. Cancer Control 2010, 17(2):120-129.
67. Rosenberg S.A., Dudley M.E. Adoptive cell therapy for the treatment of patients with metastatic melanoma. Curr Opin Immunol 2009, 21(2):233-240.
68. Wang Y., Chen H., Wu M., et al. Postoperative immunotherapy for patients with hepatocarcinoma using tumor-infiltrating lymphocytes. Chin Med J (Engl) 1997, 110(2):114-117.
69. Takayama T., Sekine T., Makuuchi M., et al. Adoptive immunotherapy to lower postsurgical recurrence rates of hepatocellular carcinoma: a randomised trial. Lancet 2000, 356(9232):802-807.
70. Lee W.C., Wang H.C., Hung C.F., et al. Vaccination of advanced hepatocellular carcinoma patients with tumor lysate-pulsed dendritic cells: a clinical trial. J Immunother 2005, 28(5):496-504.
71. Chlebowski R.T., Brzechwa-Adjukiewicz A., Cowden A., et al. Doxorubicin (75 mg/m2) for hepatocellular carcinoma: clinical and pharmacokinetic results. Cancer Treat Rep 1984, 68(3):487-491.
72. Melia W.M., Johnson P.J., Williams R. Induction of remission in hepatocellular carcinoma. A comparison of VP 16 with adriamycin. Cancer 1983, 51(2):206-210.
73. Falkson G., Ryan L.M., Johnson L.A., et al. A random phase II study of mitoxantrone and cisplatin in patients with hepatocellular carcinoma. An ECOG study. Cancer 1987, 60(9):2141-2145.
74. Colleoni M., Buzzoni R., Bajetta E., et al. A phase II study of mitoxantrone combined with beta-interferon in unresectable hepatocellular carcinoma. Cancer 1993, 72(11):3196-3201.
75. Chao Y., Chan W.K., Birkhofer M.J., et al. Phase II and pharmacokinetic study of paclitaxel therapy for unresectable hepatocellular carcinoma patients. Br J Cancer 1998, 78(1):34-39.
76. O'Reilly E.M., Stuart K.E., Sanz-Altamira P.M., et al. A phase II study of irinotecan in patients with advanced hepatocellular carcinoma. Cancer 2001, 91(1):101-105.
77. Fuchs C.S., Clark J.W., Ryan D.P., et al. A phase II trial of gemcitabine in patients with advanced hepatocellular carcinoma. Cancer 2002, 94(12):3186-3191.
78. Patt Y.Z., Hassan M.M., Aguayo A., et al. Oral capecitabine for the treatment of hepatocellular carcinoma, cholangiocarcinoma, and gallbladder carcinoma. Cancer 2004, 101(3):578-586.
79. Gish R.G., Porta C., Lazar L., et al. Phase III randomized controlled trial comparing the survival of patients with unresectable hepatocellular carcinoma treated with nolatrexed or doxorubicin. J Clin Oncol 2007, 25(21):3069-3075.
80. Louafi S., Boige V., Ducreux M., et al. Gemcitabine plus oxaliplatin (GEMOX) in patients with advanced hepatocellular carcinoma (HCC): results of a phase II study. Cancer 2007, 109(7):1384-1390.
81. Boige V., Raoul J.L., Pignon J.P., et al. Multicentre phase II trial of capecitabine plus oxaliplatin (XELOX) in patients with advanced hepatocellular carcinoma: FFCD 03-03 trial. Br J Cancer 2007, 97(7):862-867.
82. Shim J.H., Park J.W., Nam B.H., et al. Efficacy of combination chemotherapy with capecitabine plus cisplatin in patients with unresectable hepatocellular carcinoma. Cancer Chemother Pharmacol 2009, 63(3):459-467.
83. Ikeda M., Okusaka T., Ueno H., et al. A phase II trial of continuous infusion of 5-fluorouracil, mitoxantrone, and cisplatin for metastatic hepatocellular carcinoma. Cancer 2005, 103(4):756-762.